Bedrijfsoverzicht
SCYNEXIS, Inc. is a biotechnology enterprise dedicated to the research and development of pharmaceutical solutions designed to address difficult-to-treat and drug-resistant fungal infections within the United States market. The company operates specifically within the healthcare sector, focusing on the drug manufacturing industry for specialty and generic pharmaceuticals, which implies a high barrier to entry and a reliance on rigorous regulatory approval processes for its therapeutic candidates. In terms of scale, SCYNEXIS maintains a market capitalization of $44.66M while generating an annual trailing twelve-month revenue of $20.60M and employing a workforce of 18 individuals. These financial metrics indicate that the company functions as a small-cap biotechnology firm with limited market penetration relative to larger peers, suggesting that its current revenue base is primarily derived from early-stage commercialization efforts rather than broad market dominance.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $20.60M, yet this income was accompanied by a net income loss of $-8,609,000, revealing a significant disconnect between top-line sales and bottom-line profitability that points to substantial operating expenses or research and development costs consuming the majority of generated revenue. Despite the negative net income, the company generated a positive free cash flow of $599,625, which provides a degree of financial flexibility allowing the organization to fund operations or development programs without immediate reliance on external capital markets. The margin profile presents a complex picture with a gross margin of 100.0%, an operating margin of 56.4%, and a profit margin of -41.8%, indicating that while the cost of goods sold is negligible and operational efficiency before interest and taxes is high, the overall business structure currently incurs heavy expenses that erode the final profit line. On the liability side, SCYNEXIS holds $40.03M in cash against $2.17M in debt, resulting in a debt-to-equity ratio of 4.41, which suggests a balance sheet that is technically leveraged due to the ratio calculation but possesses a strong cash buffer to manage obligations. Liquidity is robust as evidenced by a current ratio of 7.04, indicating that the company holds significantly more current assets than current liabilities, ensuring it can comfortably meet short-term financial obligations. Finally, the return on equity stands at -16.5% and the return on assets is -13.4%, metrics that reveal that management is currently generating negative returns on the capital invested in the company, a common characteristic for biotechnology firms still in the development phase of their product pipelines.
Waarderingsbeoordeling
Valuation metrics for SCYNEXIS reflect the challenges of valuing an unprofitable biotechnology company, with a trailing P/E ratio of N/A and a forward P/E of -3.03, the disparity implying that the market expects earnings to improve significantly or that traditional earnings-based valuation methods are currently inapplicable due to ongoing losses. The price-to-book ratio is recorded at 0.88, which indicates that the market values the company at a discount relative to its book value, suggesting that investors are pricing in the risks associated with the company's intangible assets and potential future commercialization rather than current tangible net worth. Alternative valuation measures such as the price-to-sales ratio of 2.17 and an EV/EBITDA of N/A suggest that the market is focusing on revenue generation potential rather than current earnings power or cash flow multiples to determine fair value. Regarding price momentum, the stock has traded between a 52-week high of $1.31 and a 52-week low of $0.56, with the current market price sitting at a level that reflects the volatility typical of small-cap biotech equities trading well below their recent highs. The stock exhibits a beta of 1.15, meaning that its price volatility is 15% higher than the broader market, indicating that the share price is expected to fluctuate more aggressively than the overall market index during periods of economic uncertainty or sector-specific news.
Growth & Income
Revenue growth for the company is exceptionally high at 1808.5% year-over-year, while earnings growth is listed as N/A, implying that revenue expansion is currently outpacing the realization of profitability and that earnings are not yet growing in a traditional linear fashion due to the company's loss-making status. As a non-dividend payer, SCYNEXIS reports a dividend yield of N/A and a payout ratio of 0.0%, which explains that the company retains all of its earnings to reinvest into research, development, and commercialization activities rather than distributing income to shareholders. This strategy of reinvestment is typical for biotechnology firms where capital expenditure is directed toward advancing drug candidates through clinical trials rather than paying returns to investors. The overall growth and income profile is characterized by explosive top-line revenue expansion paired with a complete absence of dividend income, highlighting a business model focused entirely on capital appreciation and potential future product launches rather than current cash yield distribution.